Skip to main content
. 2001 Mar;69(3):1508–1514. doi: 10.1128/IAI.69.3.1508-1514.2001

FIG. 4.

FIG. 4

(A and B) Effect of anti-CTLA-4 (Fab′)2 on IFN-γ production of PBMC responding to C. neoformans. PBMC untreated or treated with C. neoformans (CBS 7698 or 6995) in the presence or absence (NS) of anti-CTLA-4 (Fab′)2 or control mouse IgG (Fab′)2 were incubated for 7 days. Supernatant fluids were harvested and tested for the presence of IFN-γ. The results are expressed as picograms of IFN-γ production per milliliter (A) or as the percentage of increase of IFN-γ production (B) of anti-CTLA-4 (Fab′)2-treated cells with respect to anti-CTLA-4 (Fab′)2-untreated cells (100%). Results represent the mean ± SE of four separate experiments from four different donors. (C and D) Effect of anti-CTLA-4 (Fab′)2 on IFN-γ production of monocytes treated with encapsulated (CBS 6995) or acapsular (CBS 7698) C. neoformans cocultured with autologous T cells for 7 days. Supernatant fluids were harvested and tested as reported above. The results are expressed as picograms of IFN-γ production per milliliter (C) or the percentage of increase of IFN-γ production (D) of anti-CTLA-4 (Fab′)2 with respect to anti-CTLA-4 (Fab′)2-untreated cells (100%). The results are the mean ± SE of three separate experiments from three different donors. ∗, P < 0.05 (CBS 6995 plus mouse anti-human CTLA-4 (Fab′)2-treated cells versus CBS 7698 plus mouse anti-human CTLA-4 (Fab′)2-treated cells).